Drug Trial Radar · NCT05275998
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Jul 5, 2022
Primary completion
Nov 20, 2024
Study completion Nov 20, 2024
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 24 weeks.
Conditions
- HIV-1-infection
Interventions
TMB-365/TMB-380Drug
Monoclonal antibodies to be given intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)Time frame: 12 weeks (Sentinel Group 1), 16 weeks (Sentinel Group 2, 3), 28 weeks (Core Group)
- Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)Time frame: Week 8
- Pharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)Time frame: Week 8, 16, and 24
- Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)Time frame: Week 8
- Pharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)Time frame: Weeks 8, 16, and 24
- Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)Time frame: Week 24
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Quest Clinical Research
San Francisco, California
CAN Community Health
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
Orlando Immunology Center
Orlando, Florida
North Texas Infectious Disease Consultants
Dallas, Texas
Crofoot Research Center, Inc.
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.